Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory

Rachael M. Crist, Jennifer Grossman, Anil K. Patri, Stęphan T. Stern, Marina A. Dobrovolskaia, Pavan P. Adiseshaiah, Jeffrey D. Clogston, Scott E. McNeil

Integrative Biology · 2012 · 259 citations · 31 references

DOIFull text

Open access

Concepts

TL;DR

The NCL’s unique set‑up allows it to test diverse nanoparticle platforms for cancer therapeutics and imaging, drawing on submissions from government, academia, and industry, and has enabled observation of safety and biocompatibility trends as well as common formulation mistakes. This article aims to share the most common pitfalls observed by the NCL in nanoparticle synthesis, purification, characterization, and analysis. Over six years, the NCL has characterized more than 250 different nanomaterials from over 75 investigators.

Abstract

The Nanotechnology Characterization Laboratory's (NCL) unique set-up has allowed our lab to handle and test a variety of nanoparticle platforms intended for the delivery of cancer therapeutics and/or imaging contrast agents. Over the last six years, the NCL has characterized more than 250 different nanomaterials from more than 75 different investigators. These submitted nanomaterials stem from a range of backgrounds and experiences, including government, academia and industry. This has given the NCL a unique and valuable opportunity to observe trends in nanoparticle safety and biocompatibility, as well as note some of the common mistakes and oversights of nanoformulation. While not exhaustive, this article aims to share some of the most common pitfalls observed by the NCL as they relate to nanoparticle synthesis, purification, characterization and analysis.

References

31